The International Myeloma Working Group (IMWG) has published dozens of research studies and treatment guidelines on multiple myeloma and its related disorders. The following are a sample of the International Myeloma Working Group’s ranging publication topics:
- Genetic predisposition for chemotherapy-induced neuropathy in multiple myeloma
- Gene signature combinations improve prognostic stratification of multiple myeloma patients
- Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
- Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: A multicenter IMWG study
- Combining Fluorescent In Situ Hybridization (iFISH) data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group (IMWG) collaborative project
From doctors to patients, the goal of these publications is to help anyone better understand aspects of myeloma. The information provided in the International Myeloma Working Group’s publications seeks to help guide patients and their doctors to treating myeloma in the most effective way for every individual case.
For decades the diagnosis of multiple myeloma required the presence of end-organ damage known as the CRAB criteria, including increased calcium level, renal dysfunction, anemia, and destructive bone lesions. The updated criteria allow for treatment of patients who are at such high risk of progression to symptomatic disease that it is clear they would benefit from therapy and also potentially live longer if they were treated before serious organ damage occurred.
The most important feature of any clinical unit established to care for myeloma patients is the training and expertise of the medical staff. Below are the diagnostic and specialty services required to support treatment decision-making and patient management. Patient support services, though desirable hallmarks of a good specialty center, are not absolutely essential.
For the more than 3% of myeloma patients who have non-secretory or oligosecretory disease, and for the majority of patients with AL amyloidosis (AL), the traditional methods of measuring circulating monoclonal immunoglobulins (electrophoresis, immunoelectrophoresis, immunofixation electrophoresis, and nephelometric measurement of immunoglobulin heavy chains of serum) are not adequate. The development of an assay that measures serum immunoglobulin-free light chains has demonstrated utility for monitoring these patients and for other specific indications, such as monitoring heavily-pretreated patients at relapse.